|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.64 USD | -3.02% |
|
-9.16% | +5.67% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +73.27% | 12 | ||||||
| 819.25 | +24.88% | 26 | ||||||
| 287.95 | +17.05% | 19 | ||||||
| 2,003,666.67 | +31.99% | 24 | ||||||
| 96.99 | +21.42% | 16 | ||||||
| 227.59 | +12.56% | 30 | ||||||
| 114.55 | -2.66% | 22 | ||||||
| 49.37 | -8.7% | 19 | ||||||
| 105.26 | +25.28% | 21 | ||||||
| 498.42 | +8.97% | 12 | ||||||
| 282.51 | +17.23% | 21 | ||||||
| 87.92 | +48.19% | 25 | ||||||
| 458,000 | +52.41% | 5 | ||||||
| 376.75 | +12.4% | 8 | ||||||
| 14.51 | +50.25% | 12 | ||||||
| - | - | 61.5 | +44.02% | 1 | ||||
| 92.5 | +2.47% | 10 | ||||||
| 72.5 | +14.53% | 2 | ||||||
| - | - | 40.3 | +41.25% | 1 | ||||
| - | - | - | - | - | ||||
| Average | 129,733.04 | +25.62% | 15 | ||||||
| Weighted average by Cap. | 260,553.63 | +20.88% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
